VialWolverine 40 mg pre-filled pen
BPC-157 + TB-500
Dual repair blend
Two repair-associated peptides in one pen.
- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Complete your setup
Pre-filled, with 4 pen needles in the box. Just add wipes.
- Alcohol Wipes
Free · To wipe the pen's rubber seal
Compare. Side by side, from the research.
About Wolverine
A combination of BPC-157 and TB-500 at 5mg each, pairing two of the most-studied repair-associated peptides. Research explores whether their distinct mechanisms are complementary.
How it works
- Complementary Mechanisms
- Pairs a compound studied for vascular and epithelial signaling with one studied for cytoskeletal regulation and cell migration.
- Single Reconstitution
- Both compounds share a vial, so a protocol using each of them requires one preparation rather than two.
What you need
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Disposable pre-filled pen · 4 pen needles included
- Strength
- 40 mg per pre-filled pen
- Storage
- Refrigerate, away from light.
- Route in research
- Subcutaneous
- SKU
- BB40DSP
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Early clinical
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
Early clinicalThe blend itself has not been studied as a combination, and published evidence for its components consists largely of BPC-157 reviews, mostly drawing on preclinical work, alongside a small human report on intra-articular BPC-157 for knee pain.
What research examines
- Musculoskeletal soft tissue healing in BPC-157 research
- Wound healing in BPC-157 research
- BPC-157 in orthopaedic sports medicine literature
- Intra-articular BPC-157 in a small knee pain report
- Actin regulation and repair-cell migration associated with TB-500
- Possible complementarity of the two mechanisms
Reported in studies
- Human safety data are limited for both components
- The BPC-157 and TB-500 combination has not been evaluated as a blend in published studies
- Recent reviews have raised open questions about the risks as well as the reported benefits of BPC-157 for musculoskeletal use
- Adverse events are not systematically summarized in the available studies
Published research protocols
1 mg, daily, am or pm
Research protocols have used 500–1,000 mcg per administration, once daily, with a loading phase before a lower-frequency maintenance phase, in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
CoreX AI
Ask about Wolverine
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with Wolverine
Vial
Vial
Vial
FAQ
Questions, answered
Wolverine, also called the Wolverine Blend, is a combination of two repair-associated research peptides, BPC-157 and TB-500, supplied at 5 mg each in a single vial. The pairing brings together two of the most-studied peptides in repair research. Research interest centers on whether their distinct mechanisms are complementary, although the combination itself has not been evaluated as a blend in published studies. It is sold for laboratory research use only.
The two compounds are studied for different steps in the repair sequence. BPC-157 has been studied for angiogenic and epithelial signaling, meaning the formation of new blood vessels and the behavior of surface tissues. TB-500 has been studied for actin regulation and the migration of repair cells, involving the cytoskeleton. Because the mechanisms differ, researchers have explored whether combining them could cover more of the repair process than either compound alone.
Most published work concerns BPC-157. Reviews have examined its role in musculoskeletal soft tissue healing and wound healing, largely based on animal studies, and a systematic review has assessed its emerging use in orthopaedic sports medicine. A small human report described intra-articular BPC-157 for several types of knee pain. TB-500 has been studied for cell migration and actin regulation. No published studies evaluate the two compounds together as a blend.
Human safety data are limited for both components, and the combination has not been studied as a blend. Adverse events are not systematically summarized in the available studies. Recent narrative and safety-focused reviews of BPC-157 and other peptide therapies for musculoskeletal injuries have raised open questions about risk as well as benefit, reflecting the small amount of controlled human evidence. Findings from animal models may not translate to humans.
Research protocols have used 500 to 1,000 mcg per administration, once daily, by the subcutaneous route, with a loading phase before a lower-frequency maintenance phase. These protocols have run in 8-week blocks followed by 4 weeks off. Because both compounds share one vial, a protocol using both requires a single reconstitution rather than two. Each CoreX order ships with a protocol guide describing the research protocol in more detail.
You may also like
Vial · Pen
Vial
Vial
Vial